134 related articles for article (PubMed ID: 27248204)
1. Third generation antiepileptic drug monotherapies in adults with epilepsy.
Mula M
Expert Rev Neurother; 2016 Sep; 16(9):1087-92. PubMed ID: 27248204
[TBL] [Abstract][Full Text] [Related]
2. New and emerging treatments for epilepsy: review of clinical studies of lacosamide, eslicarbazepine acetate, ezogabine, rufinamide, perampanel, and electrical stimulation therapy.
Chung SS; Kelly K; Schusse C
J Epilepsy Res; 2011 Dec; 1(2):35-46. PubMed ID: 24649444
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of brivaracetam compared to lacosamide, eslicarbazepine acetate, and perampanel as adjunctive treatments in uncontrolled focal epilepsy: Results of an indirect comparison meta-analysis of RCTs.
Brigo F; Bragazzi NL; Nardone R; Trinka E
Seizure; 2016 Nov; 42():29-37. PubMed ID: 27710868
[TBL] [Abstract][Full Text] [Related]
4. New developments in the management of partial-onset epilepsy: role of brivaracetam.
Coppola G; Iapadre G; Operto FF; Verrotti A
Drug Des Devel Ther; 2017; 11():643-657. PubMed ID: 28293101
[TBL] [Abstract][Full Text] [Related]
5. Tolerability of new antiepileptic drugs: a network meta-analysis.
Zaccara G; Giovannelli F; Giorgi FS; Franco V; Gasparini S; Benedetto U
Eur J Clin Pharmacol; 2017 Jul; 73(7):811-817. PubMed ID: 28378057
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.
Ben-Menachem E; Mameniškienė R; Quarato PP; Klein P; Gamage J; Schiemann J; Johnson ME; Whitesides J; McDonough B; Eckhardt K
Neurology; 2016 Jul; 87(3):314-23. PubMed ID: 27335114
[TBL] [Abstract][Full Text] [Related]
7. New antiepileptic drugs: focus on ezogabine, clobazam, and perampanel.
Rudzinski LA; Vélez-Ruiz NJ; Gedzelman ER; Mauricio EA; Shih JJ; Karakis I
J Investig Med; 2016 Aug; 64(6):1087-101. PubMed ID: 27252470
[TBL] [Abstract][Full Text] [Related]
8. A common reference-based indirect comparison meta-analysis of eslicarbazepine versus lacosamide as add on treatments for focal epilepsy.
Brigo F; Trinka E; Bragazzi NL; Nardone R; Milan A; Grillo E
Epilepsy Res; 2016 Nov; 127():12-18. PubMed ID: 27543806
[TBL] [Abstract][Full Text] [Related]
9. Comparing Safety and Efficacy of "Third-Generation" Antiepileptic Drugs: Long-Term Extension and Post-marketing Treatment.
Kwok CS; Johnson EL; Krauss GL
CNS Drugs; 2017 Nov; 31(11):959-974. PubMed ID: 29204953
[TBL] [Abstract][Full Text] [Related]
10. Safety Profile of the Newest Antiepileptic Drugs: A Curated Literature Review.
Palleria C; Cozza G; Khengar R; Libri V; De Sarro G
Curr Pharm Des; 2017; 23(37):5606-5624. PubMed ID: 28799510
[TBL] [Abstract][Full Text] [Related]
11. Perampanel for the treatment of primary generalized tonic-clonic seizures in idiopathic generalized epilepsy.
Rohracher A; Brigo F; Höfler J; Kalss G; Neuray C; Dobesberger J; Kuchukhidze G; Leitinger M; Trinka E
Expert Opin Pharmacother; 2016 Jul; 17(10):1403-11. PubMed ID: 27267634
[TBL] [Abstract][Full Text] [Related]
12. Brivaracetam: A Review in Partial-Onset (Focal) Seizures in Patients with Epilepsy.
Hoy SM
CNS Drugs; 2016 Aug; 30(8):761-72. PubMed ID: 27503181
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study.
Singh K; Shah YD; Luciano D; Friedman D; Devinsky O; Kothare SV
Epilepsy Behav; 2016 Aug; 61():41-45. PubMed ID: 27300147
[TBL] [Abstract][Full Text] [Related]
14. Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based Review.
Brodie MJ; Besag F; Ettinger AB; Mula M; Gobbi G; Comai S; Aldenkamp AP; Steinhoff BJ
Pharmacol Rev; 2016 Jul; 68(3):563-602. PubMed ID: 27255267
[TBL] [Abstract][Full Text] [Related]
15. Myoclonus and seizures in progressive myoclonus epilepsies: pharmacology and therapeutic trials.
Michelucci R; Pasini E; Riguzzi P; Andermann E; Kälviäinen R; Genton P
Epileptic Disord; 2016 Sep; 18(S2):145-153. PubMed ID: 27629998
[TBL] [Abstract][Full Text] [Related]
16. Update on the role of eslicarbazepine acetate in the treatment of partial-onset epilepsy.
Tambucci R; Basti C; Maresca M; Coppola G; Verrotti A
Neuropsychiatr Dis Treat; 2016; 12():1251-60. PubMed ID: 27307737
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Tolerability of Second and Third Generation Anti-epileptic Drugs in Refractory Epilepsy: A Network Meta-Analysis.
Zhuo C; Jiang R; Li G; Shao M; Chen C; Chen G; Tian H; Li J; Xue R; Jiang D
Sci Rep; 2017 May; 7(1):2535. PubMed ID: 28566726
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, exposure-cognition, and exposure-efficacy relationships of perampanel in adolescents with inadequately controlled partial-onset seizures.
Villanueva V; Majid O; Nabangchang C; Yang H; Laurenza A; Ferry J; Hussein Z
Epilepsy Res; 2016 Nov; 127():126-134. PubMed ID: 27595590
[TBL] [Abstract][Full Text] [Related]
19. Sleep quality and daytime sleepiness in patients treated with adjunctive perampanel for focal seizures.
Toledo M; Gonzalez-Cuevas M; Miró-Lladó J; Molins-Albanell A; Falip M; Martinez AB; Fernandez S; Quintana M; Cambrodi R; Santamarina E; Salas-Puig J
Epilepsy Behav; 2016 Oct; 63():57-62. PubMed ID: 27566967
[TBL] [Abstract][Full Text] [Related]
20. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study.
Villanueva V; Garcés M; López-González FJ; Rodriguez-Osorio X; Toledo M; Salas-Puig J; González-Cuevas M; Campos D; Serratosa JM; González-Giráldez B; Mauri JA; Camacho JL; Suller A; Carreño M; Gómez JB; Montoya J; Rodríguez-Uranga J; Saiz-Diaz R; González-de la Aleja J; Castillo A; López-Trigo J; Poza JJ; Flores J; Querol R; Ojeda J; Giner P; Molins A; Esteve P; Baiges JJ
Epilepsy Res; 2016 Oct; 126():201-10. PubMed ID: 27521586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
